AU2004226825B2 - Combinations comprising anti-epileptic drugs for the treatment of neurological disorders - Google Patents

Combinations comprising anti-epileptic drugs for the treatment of neurological disorders Download PDF

Info

Publication number
AU2004226825B2
AU2004226825B2 AU2004226825A AU2004226825A AU2004226825B2 AU 2004226825 B2 AU2004226825 B2 AU 2004226825B2 AU 2004226825 A AU2004226825 A AU 2004226825A AU 2004226825 A AU2004226825 A AU 2004226825A AU 2004226825 B2 AU2004226825 B2 AU 2004226825B2
Authority
AU
Australia
Prior art keywords
epilepsy
administered
combination according
combination
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004226825A
Other languages
English (en)
Other versions
AU2004226825A1 (en
Inventor
David Aitken
Kurt Lingenhohl
Markus Schmutz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2004226825A1 publication Critical patent/AU2004226825A1/en
Application granted granted Critical
Publication of AU2004226825B2 publication Critical patent/AU2004226825B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AU2004226825A 2003-04-04 2004-04-02 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders Ceased AU2004226825B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0307860.7A GB0307860D0 (en) 2003-04-04 2003-04-04 Organic compounds
GB03/078,60.7 2003-04-04
PCT/EP2004/003518 WO2004087161A1 (en) 2003-04-04 2004-04-02 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders

Publications (2)

Publication Number Publication Date
AU2004226825A1 AU2004226825A1 (en) 2004-10-14
AU2004226825B2 true AU2004226825B2 (en) 2007-08-16

Family

ID=9956223

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004226825A Ceased AU2004226825B2 (en) 2003-04-04 2004-04-02 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders

Country Status (10)

Country Link
US (1) US20060194766A1 (enExample)
EP (1) EP1620103A1 (enExample)
JP (1) JP2006522062A (enExample)
CN (1) CN100546581C (enExample)
AU (1) AU2004226825B2 (enExample)
BR (1) BRPI0409170A (enExample)
CA (1) CA2521274A1 (enExample)
GB (1) GB0307860D0 (enExample)
MX (1) MXPA05010707A (enExample)
WO (1) WO2004087161A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP2164489A2 (en) * 2007-07-13 2010-03-24 Eisai R&D Management Co., Ltd. Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder
PL3061821T3 (pl) 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
CN112789042A (zh) 2018-09-28 2021-05-11 卡鲁娜治疗学有限公司 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864536A (en) * 1957-11-06 1961-04-06 Sapos S A Lab ª‡-ethyl-phenylacetylurea
US3489836A (en) * 1964-01-06 1970-01-13 Ici Ltd 5-amino - 10,11-dihydro - 5h - dibenzo (a,d)-cycloheptenes and derivatives in pharmaceutical compositions and the use thereof for the treatment of epilepsy
WO1989005642A1 (en) * 1987-12-22 1989-06-29 Ferkany John W Dextrorphan potentiator for anticonvulsant composition and method
US5095033A (en) * 1991-03-01 1992-03-10 Laboratoires Biocodex Method for treating epilepsy
EP0637449A1 (en) * 1993-07-06 1995-02-08 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of L-carnitine or acyl L-carnitines and valproate for treating seizure disorders
WO1998017692A1 (en) * 1996-10-19 1998-04-30 University Of Wales, Bangor Preparation of chemically reactive polysaccharides
CN1265889A (zh) * 1999-03-06 2000-09-13 王学勇 一种治疗癫痫病的药物
WO2001039779A1 (en) * 1999-12-01 2001-06-07 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
WO2002003915A2 (en) * 2000-07-10 2002-01-17 Kozachuk Walter E Methods of producing weight loss and treatment of obesity
WO2003042182A1 (en) * 2001-11-12 2003-05-22 Novartis Ag Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199900897T2 (xx) * 1996-10-24 1999-07-21 Novartis Ag Ornat�lm�� aminoalkanfosfonik asitler.
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864536A (en) * 1957-11-06 1961-04-06 Sapos S A Lab ª‡-ethyl-phenylacetylurea
US3489836A (en) * 1964-01-06 1970-01-13 Ici Ltd 5-amino - 10,11-dihydro - 5h - dibenzo (a,d)-cycloheptenes and derivatives in pharmaceutical compositions and the use thereof for the treatment of epilepsy
WO1989005642A1 (en) * 1987-12-22 1989-06-29 Ferkany John W Dextrorphan potentiator for anticonvulsant composition and method
US5095033A (en) * 1991-03-01 1992-03-10 Laboratoires Biocodex Method for treating epilepsy
EP0637449A1 (en) * 1993-07-06 1995-02-08 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of L-carnitine or acyl L-carnitines and valproate for treating seizure disorders
WO1998017692A1 (en) * 1996-10-19 1998-04-30 University Of Wales, Bangor Preparation of chemically reactive polysaccharides
CN1265889A (zh) * 1999-03-06 2000-09-13 王学勇 一种治疗癫痫病的药物
WO2001039779A1 (en) * 1999-12-01 2001-06-07 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
WO2002003915A2 (en) * 2000-07-10 2002-01-17 Kozachuk Walter E Methods of producing weight loss and treatment of obesity
WO2003042182A1 (en) * 2001-11-12 2003-05-22 Novartis Ag Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Acta Neurologica Scandinavia Supplementum 69(99) (1984) pp 19-22 *
Arzneimittelwirkungen - Lehrbuch der Pharmakologie und Toxikologie (1977) pp 252-260 *
Bioorganic & Medicinal Chemistry Letters 9(2) (1999) pp 249-254 *
DWPI Abst no 2000-673134 & CN 1265889 A *
Epilepsia 2000 United States 41(11) (2000) pp 1364-1374 *
European Jornal of Pharmacology 281(3) (1995) pp 319-326 *
European Journal of Pharmacology 359(2-3) (1998) pp 103-109 *
Polish Journal of Pharmacology 53(2) (2001) pp 101-108 *
Polish Journal of Pharmacology 55(1) (2003) pp 103-107 *
Polish Journal of Pharmacology and Pharmacy 44(suppl) (1992) pp 258-259 *
The Merck Manualpp 1406-1408 *

Also Published As

Publication number Publication date
BRPI0409170A (pt) 2006-04-11
MXPA05010707A (es) 2005-12-12
WO2004087161A1 (en) 2004-10-14
CA2521274A1 (en) 2004-10-14
JP2006522062A (ja) 2006-09-28
GB0307860D0 (en) 2003-05-14
AU2004226825A1 (en) 2004-10-14
EP1620103A1 (en) 2006-02-01
US20060194766A1 (en) 2006-08-31
CN100546581C (zh) 2009-10-07
CN1767832A (zh) 2006-05-03

Similar Documents

Publication Publication Date Title
DK2035029T3 (en) PEPTID RELATIONS FOR TREATMENT OF REFRACTOR STATUS EPILEPTICUS.
JP2007517901A (ja) 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
US20100179129A1 (en) Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2003092682A1 (en) Zonisamide use in obesity and eating disorders
CN101420958A (zh) 共投与腺苷a1受体拮抗剂和抗惊厥药
JP2009539996A (ja) 腎機能障害を持つ個体における利尿改善方法
AU2004226825B2 (en) Combinations comprising anti-epileptic drugs for the treatment of neurological disorders
AU2004290890B2 (en) Combinations comprising AMPA receptor antagonists for the treatment of schizophrenia
CA2522971A1 (en) Method of improved diuresis in individuals with impaired renal function
CA2568436A1 (en) Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
US20080242684A1 (en) Methods of administration of adenosine a1 receptor antagonists
WO2005049042A1 (en) Combinations comprising ampa receptor antagonists for the treatment of tinnitus
WO2005049041A1 (en) Combinations comprising ampa receptor antagonists for the treatment of anxiety disorders
WO2005049039A1 (en) Combinations comprising ampa receptors antagonists for the treatment of affective and attention deficit disorders
WO2005094797A2 (en) Use of ampa-receptor antagonists for treating dementia
WO2004105756A2 (en) Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof
WO2005097138A2 (en) Combinations comprising oxcarbazepine to treat affective disorders
WO2005039594A1 (en) Combinations comprising ampa receptor antagonists for the treatment of myopia
WO2005039593A1 (en) Combinations comprising ampa receptor antagonists for the treatment of neuropathic pain
MXPA06007770A (en) Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
MXPA02005071A (es) Composiciones y metodos para el tratamiento o prevencion de convulsiones o ataques
EP1932529A1 (en) Method of improved diuresis in individuals with impaired renal function

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired